Comparison · NCT00548197-80066ecf
Intervention Group vs Control Group: Anatomic Status of the Retina
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention Group vs Control Group: Anatomic Status of the Retina. Trial comparisons, record NCT00548197-80066ecf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00548197-80066ecf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.149 | wilson | |
| Risk in group 2 | 0.389 | 0.203 | 0.614 | wilson | |
| Risk difference, group 1 minus group 2 | -0.389 | -0.614 | -0.151 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Intervention Group than on Control Group | 2.57 | 1.63 | 6.63 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention Group | Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy~Bevacizumab: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy | 0 | 22 | OG000 |
| Group 2 | Control Group | no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy | 7 | 18 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Anatomic Status of the Retina
- Description
- Number of Participants with Postoperative Vitreous Hemorrhage
- Time frame
- Last follow up, an average of 7 months post-operation
- Population
- Postoperative Vitreous Hemorrhage
Source ClinicalTrials.gov
Trial
- Title
- Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
- NCT number
- NCT00548197
- Phases
- PHASE1
- Conditions
- Intravitreal Bevacizumab Injection, Pars Plana Vitrectomy, Tractional Retinal Detachment, Diabetic Retinopathy
- Interventions
- Bevacizumab
- Lead sponsor
- Iran University of Medical Sciences
- Results first posted
- 2018-10-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00548197?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00548197-80066ecf